Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30079633 | 1.00 | MAPT (0.36) | MAPTNPSR1RXFP1PARP1NR3C1 | |
| SCHEMBL153211 | 0.79 | AHR (0.45) | MAPTNPSR1RXFP1PARP1NR3C1 | |
| SCHEMBL30748780 | 0.76 | PARP1 (0.42) | MAPTNPSR1RXFP1PARP1NR3C1 | |
| SCHEMBL31394015 | 0.76 | MAPT (0.36) | MAPTNPSR1RXFP1PARP1NR3C1 | |
| SCHEMBL30768351 | 0.76 | PARP1 (0.39) | MAPTNPSR1RXFP1PARP1NR3C1 | |
| SCHEMBL6342164 | 0.76 | MAPT (0.36) | MAPTNPSR1RXFP1PARP1NR3C1 | |
| SCHEMBL14758337 | 0.76 | MAPT (0.36) | MAPTNPSR1RXFP1PARP1NR3C1 | |
| SCHEMBL4100100 | 0.76 | PARP1 (0.39) | MAPTNPSR1RXFP1PARP1NR3C1 | |
| SCHEMBL21893243 | 0.76 | ALOX15 (0.40) | MAPTNPSR1RXFP1PARP1NR3C1 | |
| SCHEMBL26230380 | 0.76 | PARP1 (0.35) | PARP1NR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12410160-B2 | KHK inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4313967-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117120429-A | KHK inhibitor | 吉利德科学公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230079863-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. | 2023-03-16 | — | — | US | disclosed |
| CN-110964023-B | Fused tetracyclic compounds and application thereof in medicines | 广东东阳光药业有限公司 | 2022-12-27 | — | — | CN | disclosed |
| WO-2022212194-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022212194-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| CN-113135937-A | Fused tetracyclic compounds and application thereof in medicines | 广东东阳光药业有限公司 | 2021-07-20 | — | — | CN | disclosed |
| CN-110964023-A | Fused tetracyclic compounds and application thereof in medicines | 广东东阳光药业有限公司 | 2020-04-07 | — | — | CN | disclosed |
| WO-2020063870-A1 | FUSED TETRACYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020063870-A1 | FUSED TETRACYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-04-02 | — | — | WO | disclosed |
| WO-2018102358-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2018102399-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2012074980-A2 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISORDERS AND LIVER DISORDERS USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2010141696-A1 | METHODS OF TREATING OR PREVENTING PSORIASIS, AND/OR ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2009010139-A2 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-01-22 | — | — | WO | disclosed |
| EP-1414809-B1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | BAYER CORP (US) | 2008-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | MAPT 1585/4885NPSR1 3868/4885RXFP1 1113/4885 |
| US-20230079863-A1 | KHK INHIBITORS | KHK, KHDRBS1, NADK | MAPT 3104/4885NPSR1 3300/4885RXFP1 4768/4885 |
| US-12410160-B2 | KHK inhibitors | KHK, KHDRBS1, NADK | MAPT 3104/4885NPSR1 3300/4885RXFP1 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.